Polyplus Transfection said this week that it has raised €2.5 million ($3.3 million) through a round of private financing.

The round brings in new investors Alsace Inter Regio Fonds d’Investissement and Sudinnova, while existing investors CIC Vizille Capital Innovation and CIC Finance also participated.

The company said it will use the funds to advance new siRNA delivery compounds and add 10 new researchers and lab technicians, which would bring its total headcount to 40.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.